Nivolumab,Ipilimumab
BMS
['thanks', 'congrat']
 congrats to the authors. we look forward to hearing next year on the ci-primary endpoint results and see the next confirmatory trial. thanks for the great insights on this neoadjuvant setting: 
Independent and international experts in GI oncology supporting medical oncologists to give the best possible care to patients. Part of https://t.co/Y8pV8OaxOB